Roquefort Therapeutics plc
Research - London, England, United Kingdom
Roquefort Therapeutics plc Employees
Roquefort Therapeutics plc Details
Roquefort Therapeutics is a LSE Main Market listed biotech company developing products through the pre-clinical phase prior to partnering or selling to big pharma. The Company's wholly owned subsidiary, LYRAMID, is a pre-clinical biotech company focused on developing first in class Midkine inhibiting nucleic acid-based drugs for the treatment of cancer, chronic inflammatory, autoimmune disorder and COVID-19. Recent progress within nucleic acid-based drugs has led to a reduction in drug development timelines and costs, increasing the chance of early value creation.Through extensive research resulting in validation through publication in over 1,000 scientific journals, LYRAMID has identified the potential to exploit the broad therapeutic potential of Midkine for a number of clinical indications of unmet needs. LYRAMID holds the largest global IP portfolio on Midkine. The Midkine blocking drug development markets have significant global market potential (in the multi-billion dollars). Lyramid's pre-clinical programme is currently underway with an initial focus on cancer (including immunotherapy resistance) and COVID-19.
Roquefort Therapeutics plc Technologies
Email Providers
Outlook
Load Balancers
Varnish
CMS
Wix
Advertising Networks
Advertising.com
Other
Mobile Friendly